Schizophrenia
Conditions
Keywords
Iloperidone, Risperidone, PANSS
Brief summary
This research is a Randomized, double-blind, risperidone-controlled, multicenter clinical study. Chinese subjects with Ischemic Schizophrenia.
Detailed description
Subjects will randomly enter into one of two groups,the period of treatment is 8 weeks.
Interventions
DRUGIloperidone
DRUGRisperidone
Sponsors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* men and women aged 18 to 65 years with schizophrenia; * PANSS total score of at least 70 at screening and baseline; * at least 2 more than 4 points in 7 of PANSS-P; * informed consent.
Exclusion criteria
* allergy with iloperidone or risperidone; * psychotic symptoms failing to improve after sufficient exposure to 2 antipsychotic treatment; * any other primary Axis 1 psychiatric diagnosis; * a history of alcohol or drug dependence in recent 1 year; * at imminent risk of harm to self or others; * systolic blood pressure≤90mmHg。
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the score of Positive and Negative syndrome scale to evaluation the severity of schizophrenia | 8 weeks |
Secondary
| Measure | Time frame |
|---|---|
| the score of clinical global impressions to evaluation the severity of illness | 8 weeks |
| the score of clinical global impressions to evaluation the improvement of illness | 8 weeks |
Countries
China
Contacts
Primary ContactWang yu mei, master
Outcome results
None listed